Vir Biotechnology Shares Slide 16.5% Following $150 Million Stock Offering

Shares of Vir Biotechnology, Inc. tumbled 16.58% to $10.11 during Friday premarket trading following the announcement of a $150 million public stock offering. The clinical-stage biopharmaceutical company priced 15 million common shares at $10 each, triggering concerns among investors regarding potential equity dilution.

Under the terms of the transaction, the firm anticipates generating $150 million in gross proceeds prior to accounting for underwriting discounts, commissions, and related expenses. Additionally, the company provided underwriters with a 30-day option to acquire up to 2.25 million extra shares at the established offering price. The financing round is slated to conclude on November 16, pending standard closing conditions, with institutions including Leerink Partners, Morgan Stanley, and Evercore ISI acting as bookrunning managers.

Despite the immediate pricing pressure, the firm continues to advance its clinical pipeline. Vir recently reported positive Phase 3 data for its hepatitis delta combination treatment, alongside securing FDA Fast Track designation for its prostate cancer candidate VIR-5500. Wall Street analysts maintain a consensus Buy rating on the stock, with average price targets sitting near $24.

• Stock Move: Down 16.58% in premarket trading to $10.11.
• Offering Details: 15 million shares priced at $10 each to raise $150 million.
• Key Technical Levels: Immediate support observed at $8.50, with resistance noted near $12.

What to watch next: Monitor the official closing of the equity offering on November 16 and whether the stock holds its key technical support level at $8.50.